Healthcare Research | Market Insights & Strategic Analysis

  The   malignant mesothelioma market size   reached a value of USD 6.5 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 12.8 Billion by 2035, exhibiting a growth rate (CAGR) of 6.3% during 2025-2035. As diagnosed cases increase, with more effective treatments being developed and diagnostic capabilities improving, the malignant mesothelioma market is set to receive greater focus in 2025. It is a rare form of cancer with a very aggressive pathology, often caused by asbestos exposure, and affects the lung lining, abdomen, and heart. The low incidence rate due to lack of awareness has started changing, which in turn is leading to increased investment in care solutions globally. Shrinking Lag Time & Increasing Awareness While the malignant mesothelioma is still on the rise, there is hope in the form of a pending public health initiative. In countries where asbestos is banned, the m...

The top 7 (US, EU4, UK, and Japan) post-bariatric hypoglycemia markets are expected to exhibit a CAGR of 5.12% during 2025-2035. Ongoing research shows that the market for post-bariatric hypoglycemia (PBH) is set to increase by 2025 as more people undergo bariatric surgery and develop metabolic complications. PBH poses certain challenges due to its unique nature. Gastric bypass surgery patients experience low blood sugar levels after a meal. Improved diagnosis, better education, emerging treatments, integrated digital tools, and evolving care pathways are shaping the future of this condition.   Rising Prevalence and Clinical Recognition   Greater access to healthcare services has led to an increase in the number of bariatric surgeries performed in the last decade. During this time, focus on PBH has been on the rise. While the majority of these patients enjoy the benefits, a small but growing subset complain of dizziness, sweating, irritability, or even fainting durin...

  The top 7 (US, EU4, UK, and Japan)   penile cancer markets size   are expected to exhibit a CAGR of 4.95% during 2025-2035. The global focus on the oncology segment of the penile cancer market is increasing due to heightened awareness and improved diagnostic methods. While the prevalence of penile cancer is much lower than other urological cancers, its effects are devastating both physically and psychologically. The market is evolving gradually as the  incidence of the disease increases in certain areas, as well as detection strategies being implemented, investment in targeted therapy, and early intervention.  The increasing incidence of this type of cancer is emerging as one of the attempts to target the void in medical healthcare services. It can be attributed to several factors, inadequate hygiene, chronic HPV, smoking, and phimosis. This issue is more pronounced in the lower to middle class income countries due to lack of access to healthcare. Having said ...

  The   type 1 diabetes market size   reached a value of USD 5.9 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 9.6 Billion by 2035, exhibiting a growth rate (CAGR) of 4.65% during 2025-2035. The Type 1 diabetes market in 2025 is set to undergo a profound shift as a result of increasing numbers of diabetes cases, advancements in technology, and new treatment paradigms. The autoimmune disorder known as Type 1 diabetes is now being diagnosed in people of all ages. This, in turn, is widening the healthcare scope as there is a burgeoning need for innovative treatments, including proactive remote care and compassionate diabetes management. New Developments in the Type 1 Diabetes Market The increased use of hybrid closed-loop insulin delivery systems will be one of the hallmark changes. Often referred to as “artificial pancreas,” these complex devices automatically dose insulin based o...

  The 7 major   paroxysmal nocturnal hemoglobinuria markets   reached a value of US$ 2.9 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach US$ 6.9 Billion by 2035, exhibiting a growth rate (CAGR) of 8.29% during 2025-2035. The Paroxysmal Nocturnal Hemoglobinuria (PNH) market is changing the most in 2025 due to treatment options, an increasing patient population, and technological advancements. PNH is a rare blood disorder where the patient suffers from the destruction of red blood cells leading to anemia, fatigue and in some cases, dangerous blood clots. In this article, we take a look at the everchanging market’s trends, study the reasons driving the growing incidence, and focus on the latest technological advances in PNH. Evolving Trends in PNH Market The use of Complement Inhibition therapy is one of the most prevalent trends in the PNH market. These include the already established treatments eculizumab and ravulizumab, as well as newer treatments ...

  The   dyspnea market size   reached a value of USD 6,893.2 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 11,827.3 Million by 2035, exhibiting a growth rate (CAGR) of 5.03% during 2025-2035. Changes in the healthcare sector, greater prevalence of respiratory and cardiovascular diseases, and faster technological progress are all contributing factors to the shift in the dyspnea market in 2025. Shortness of breath, or dyspnea, as it is referred to in clinical terms, impacts hundreds of millions globally. The ongoing changes are also improving diagnosis, treatment, and overall market growth. This article uses plain wording that is optimized for search relevance to discuss the driving factors for rising incidences and new technological innovations shaping the dyspnea market. Current Trends in the Dyspnea Market Due to a greater focus on proactive identification and effective treatme...